pharmaphorum April 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
If borne out in additional, larger trials, the finding could see the end of a decades-long effort to find a therapy for Parkinson’s that could offer a neuroprotective effect, rather than simply treating symptoms like muscle tremors.
Lixisenatide is an older drug in the same class as Novo Nordisk’s big-selling Ozempic/Wegovy (semaglutide), used to treat type 2 diabetes and obesity, as well as to reduce the risk of cardiovascular disease in some overweight patients.
It has also been shown to reduce kidney disease-related events in people with type 2 diabetes...
Today's Sponsors
Today's Sponsor